EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Amphotericin B in the Era of New Antifungals: Where Will It Stand?

Karolina Akinosoglou iD, Emmanouil Angelos Rigopoulos, Despoina Papageorgiou, Georgios Schinas iD, Eleni Polyzou, Effrosyni Dimopoulou, Charalambos Gogos, George Dimopoulos

Journal of Fungi · 10.04.2024 · 10 (4) · 278

DOI: 10.3390/jof10040278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Fungi, online erschienen am 10.04.2024. Verfasst von Karolina Akinosoglou und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Patras, 26504 Patras, Greece. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amphotericin B (AmB) has long stood as a cornerstone in the treatment of invasive fungal infections (IFIs), especially among immunocompromised patients. However, the landscape of antifungal therapy is evolving. New antifungal agents, boasting novel mechanisms of action and better safety profiles, are entering the scene, presenting alternatives to AmB’s traditional dominance. This shift, prompted by an increase in the incidence of IFIs, the growing demographic of immunocompromised individuals, and changing patterns of fungal resistance, underscores the continuous need for effective treatments. Despite these challenges, AmB’s broad efficacy and low resistance rates maintain its essential status in antifungal therapy. Innovations in AmB formulations, such as lipid complexes and liposomal delivery systems, have significantly mitigated its notorious nephrotoxicity and infusion-related reactions, thereby enhancing its clinical utility. Moreover, AmB’s efficacy in treating severe and rare fungal infections and its pivotal role as prophylaxis in high-risk settings highlight its value and ongoing relevance. This review examines AmB’s standing amidst the ever-changing antifungal landscape, focusing on its enduring significance in current clinical practice and exploring its potential future therapeutic adaptations.

Schlagwörter

Stichwörter der Autor:innen

amphotericin Bantifungal agentsdrug resistanceepidemiologyfungalfungal infectionsimmunocompromised hostliposomesmycosesprophylactic treatment

Autor:innen und Institutionen

  • School of Medicine, University of Patras, 26504 Patras, Greece.
  • Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece.
  • Hellenic Institute for the Study of Sepsis, 11528 Athens, Greece.
  • 3rd Department of Critical Care, Evgenidio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.

ORCID-Profile: Karolina Akinosoglou, Georgios Schinas

Zitieren

APA

Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C., & Dimopoulos, G. (2024). Amphotericin B in the Era of New Antifungals: Where Will It Stand?. Journal of Fungi, 10(4), 278. https://doi.org/10.3390/jof10040278

Vancouver

Akinosoglou K, Rigopoulos EA, Papageorgiou D, Schinas G, Polyzou E, Dimopoulou E, et al. Amphotericin B in the Era of New Antifungals: Where Will It Stand?. Journal of Fungi. 2024;10(4):278. doi:10.3390/jof10040278

BibTeX
@article{Akinosoglou2024,
  author = {Akinosoglou, Karolina and Rigopoulos, Emmanouil Angelos and Papageorgiou, Despoina and Schinas, Georgios and Polyzou, Eleni and Dimopoulou, Effrosyni and Gogos, Charalambos and Dimopoulos, George},
  title = {Amphotericin B in the Era of New Antifungals: Where Will It Stand?},
  journal = {Journal of Fungi},
  year = {2024},
  volume = {10},
  number = {4},
  pages = {278},
  doi = {10.3390/jof10040278}
}
Kostenlos starten →